PharmiWeb6h
Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE®
Regulatory ApprovalFormycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE® 25.02.2025 / 06:30 CET/CESTThe issuer is solely ...
EQS-News: Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE®
EQS-News: Formycon AG / Key word (s): Regulatory Approval Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE® ...
globes.co.il18h
Mon: TASE continues to lose ground
Bank Leumi (TASE: LUMI) led the market today, falling 1.02% on the day's biggest trading turnover. Bank Hapoalim (TASE: POLI) fell 1.37%, Mizrahi Tefahot Bank fell 0.53% and Israel Discount Bank (TASE ...
PharmiWeb22h
Asthma & COPD Drugs Market Share & Forecast 2034
Vantage Market Research is pleased to announce the publication of its latest report, Asthma and COPD Drugs Market. This ...